Bladder Cancer Coverage from Every Angle

Recent News

GU Symposium 2021: Neoadjuvant Durvalumab Plus Chemotherapy in Muscle-Invasive Urothelial Carcinoma
Are There Racial Disparities in BCG Treatment of Non–Muscle Invasive Bladder Cancer?
Durvalumab Indication Withdrawn in Advanced Bladder Cancer in the United States
GU Symposium 2021: Novel IL-15 Superagonist for Non–Muscle-Invasive Bladder Cancer
Does Biologic Sex Influence Progression of Bladder Cancer After BCG Treatment?
GU Symposium 2021: Enfortumab Vedotin Versus Chemotherapy for Advanced Urothelial Carcinoma
GU Symposium 2021: Impact of Gender on Surgical Outcomes After Radical Cystectomy
GU Symposium 2021: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Cancer
Proliposomal Paclitaxel in Non–Muscle Invasive Bladder Cancer: Study Supports Move to Phase IIb
Durvalumab-Based Combination Therapy in Non–Muscle Invasive Bladder Cancer
Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma
FDA Brief: Novel Treatment of Upper Tract Urothelial Cancer Granted Fast Track Designation
Chronic Kidney Disease: Risk Factor for Muscle-Invasive Bladder Cancer?
Does Cystectomy Delay Affect Mortality in Bladder Cancer?
Neoadjuvant Chemotherapy Deferral in Patients Undergoing Cystectomy for Bladder Cancer
Are Individuals With Multiple Sclerosis at Higher Risk of Developing Bladder Cancer?
Kidney-Sparing Alternative Treatment of Low-Grade Upper Tract Urothelial Carcinoma
Are There Racial Disparities in Mortality in Muscle-Invasive Bladder Cancer?
Avelumab Plus Axitinib Under Study in Urothelial Cancer
Ureteral Obstruction Prior to Chemotherapy for Muscle-Invasive Bladder Cancer
Combination Immunotherapy for Urothelial Carcinoma: Phase Ib Interim Analysis
DDR Alterations and Outcomes With Immunotherapy for Advanced Urothelial Cancer
JAVELIN Bladder 100: Avelumab Maintenance for Advanced Urothelial Carcinoma
ADP-A2M10 Dose-Escalation Trial in MAGE-A10–Positive Urothelial Tumors
HER2-Targeting Antibody-Drug Conjugate in Advanced Urothelial Carcinoma
Are High 12-Chemokine Scores Prognostic in Muscle-Invasive Bladder Cancer?
Neoadjuvant Ipilimumab Plus Nivolumab Under Study in Urothelial Carcinoma
SITC 2020: Tumor Mutation Burden and Response to Immunotherapy in Advanced Urothelial Cancer
ASTRO 2020: Combination Radiotherapy and Durvalumab in Localized Bladder Cancer
Neoadjuvant Dual Checkpoint Blockade for High-Risk Urothelial Carcinoma
ASTRO 2020: Bladder-Sparing Radiochemotherapy Regimens Under Study
ASTRO 2020: Predicting Survival Outcomes in Bladder Cancer Using Urinary Tumor DNA
Novel Urine DNA Methylation Assay Under Study in Bladder Cancer
ASTRO 2020: Outcomes With Radiotherapy in Men and Women With Urothelial Bladder Cancer
FDA in Brief: Draft Guidance for Uniform Approach to Clinical Trials in Bladder Cancer
Extended Follow-up With Nivolumab Plus Ipilimumab in Advanced Urothelial Cancer
Enfortumab Vedotin in Previously Treated Advanced Urothelial Cancer: Update From EV-201
Concurrent Nivolumab and Radiotherapy in Elderly Patients With Bladder Cancer
ESMO 2020: Link Between TMB and Pembrolizumab Response in Urothelial Cancer?
Durvalumab Plus Cabozantinib in Advanced Urothelial Cancer: ARCADIA Trial
Whole-Genome Sequencing Via Urine: Novel Modality for Detecting Urothelial Carcinoma
Effect of Proton Pump Inhibitors on Response to Atezolizumab in Urothelial Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.